Literature DB >> 6253568

Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes.

R J McDonough, J J Madden, A Falek, D A Shafer, M Pline, D Gordon, P Bokos, J C Kuehnle, J Mendelson.   

Abstract

Street opiate addiction produces a significant depression in the absolute number of total T lymphocytes in peripheral blood as measured by the ability of the lymphocytes to rosette sheep red blood cells (SRBC). Associated with the decrease in T cells, there is an increase in the absolute number of null lymphocytes but no significant changes in B lymphocytes or total white blood cell count. The T cell values for 2 different populations of addicts (n = 12 and 32) are 31.8% and 23.1%, whereas the null cell values are 51.1% and 57.6%, respectively. The values for comparable control populations (n = 18 and 10) are: T% = 70.7% and 67.4%, and null % = 9.2% and 14.5%. Self-reported use of marihuana does not significantly alter the distribution of cell populations. A 1- to 3-hr incubation of addicted-derived lymphocytes with 10(-6) to 10(-7) M Naloxone reverses both T cell depression and null cell increase by allowing the null cells to express SRBC receptors. Cyclic AMP and dibutyryl cyclic AMP can also convert the null cells to T cells. The conversion of null to T lymphocytes has additionally been measured by monitoring the increase in PHA-stimulated growth in 72-hr cultures as determined by tritiated thymidine incorporation into DNA. These results support the hypothesis that opiates can alter T lymphocyte number and function in vivo, and that this alteration may produce a significant degeneration in the immune competence of street opiate addicts.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253568

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Total intravenous anesthesia combined with epidural eptazocine.

Authors:  S Aida; T Tomiyama; K Shimoji
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

2.  Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution?

Authors:  V V Lukashov; J Goudsmit
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

4.  Systemic candidiasis in heroin addicts.

Authors:  R J Hay
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-26

5.  Conditioned effects of heroin on the expression of inducible nitric oxide synthase in the rat are susceptible to extinction and latent inhibition.

Authors:  Jennifer L Szczytkowski; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

6.  Ultrastructural study of pseudo-Kaposi's sarcoma (Bluefarb-Stewart type).

Authors:  M Fimiani; S Simoni; C Miracco; M De Santi; P Luzi; L Andreassi
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  Immunomodulatory activity of mu- and kappa-selective opioid agonists.

Authors:  D D Taub; T K Eisenstein; E B Geller; M W Adler; T J Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

8.  Evidence for an inhibitory role of beta-endorphin and other opioids on human total T rosette formation.

Authors:  C De Carolis; G De Sanctis; R Perricone; C Moretti; A Fabbri; L Gnessi; F Fraioli; L Fontana
Journal:  Experientia       Date:  1984-07-15

9.  Polyclonal T cell elimination by prolonged immunostimulation in an experimental model.

Authors:  F Galdiero; M Galdiero; I Nuzzo; M Vitiello; C Bentivoglio; C Romano-Carratelli
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  Drug use patterns: implications for the acquired immunodeficiency syndrome.

Authors:  L S Brown; R Evans; D Murphy; B J Primm
Journal:  J Natl Med Assoc       Date:  1986-12       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.